---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-23-000077"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:47:11.620529+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pacira Q3 net income $10.9M, cuts FY EXPAREL guidance; CEO Stack to retire

## Summary
- Total revenues $163.9M, down ~2% YoY; EXPAREL sales $128.7M, down from $132.6M.
- GAAP net income $10.9M ($0.23/sh) vs net loss $0.7M in Q3 2022; adjusted EBITDA $52.9M.
- Lowers FY 2023 EXPAREL net product sales guidance to $535-540M from prior $550-560M.
- CEO Dave Stack will retire; remains until successor appointed, then consulting through Aug 2025.
- PDUFA action date for EXPAREL lower extremity nerve block on track for Nov 13, 2023.

## SEC filing metadata
- accession: 0001396814-23-000077
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000077/0001396814-23-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000077/pcrx-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-23-000077
- JSON: https://secwatch.observer/filing/0001396814-23-000077.json
- Plain text: https://secwatch.observer/filing/0001396814-23-000077.txt

## Key facts
- Earnings Releases
  Pacira BioSciences, Inc. reported financial results for third quarter of 2023.
  - Period: third quarter of 2023
  - Result: reported results
  source text: Total revenues were $163.9 million in the third quarter of 2023, versus $167.5 million reported for the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000077/0001396814-23-000077-index.htm
- Earnings Releases
  Pacira BioSciences, Inc. reported financial results for third quarter of 2023.
  - Period: third quarter of 2023
  - Result: reported results
  source text: GAAP net income was $10.9 million, or $0.23 per share (basic and diluted) in the third quarter of 2023, compared to a net loss of $0.7 million, or $(0.02) per share (basic and diluted) in the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000077/0001396814-23-000077-index.htm
- Earnings Releases
  Pacira BioSciences, Inc. reported full-year 2023 results: revenue EXPAREL net product sales of $535 million to $540 million. Guidance lowered.
  - Period: full-year 2023
  - Revenue: EXPAREL net product sales of $535 million to $540 million
  - Guidance: lowered
  - Result: guidance update
  source text: Pacira now expects full-year EXPAREL net product sales of $535 million to $540 million versus the company's previously guided range of $550 million to $560 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000077/0001396814-23-000077-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.